Latest Conference Coverage

Earlier Initiation of Ublituximab Results In Improved Disease Outcomes in Treatment-Naïve Multiple Sclerosis

Patients with first MS symptoms less than 3 years prior to enrollment saw greater long-term benefits with ublituximab than those with longer disease course.

Pooled Phase 3 Studies Highlight AXS-07 as Effective Migraine Treatment

In the phase 3 MOMENTUM and INTERCEPT studies, patients treated with AXS-07 saw reductions in headache pain freedom, most bothersome symptoms, and use of rescue medications.

Bridging Engineering and Neuroscience in the Creation of Artificial Axons for Myelination Research: Krystyn J. Van Vliet, PhD & Anna Jagielska, PhD, MSc

The professor of materials science and engineering at Cornell University and chief executive officer at Artificial Axon Labs talked about the development of artificial axons through 3D printing. [WATCH TIME: 6 minutes]

Reevaluating Neuroprotective Multiple Sclerosis Trial Designs Using the Visual System: Shiv Saidha, MBBCh

The professor of neurology at Johns Hopkins Medicine discussed the trial design of the phase 4 RENEW study assessing the long-term safety profile of mitoxantrone in multiple sclerosis. [WATCH TIME: 9 minutes]

The Potential of NLRX1 in Immune Regulation and Neuroprotection for Inflammatory Neurodegenerative Disorders: Marjan Gharagozloo, PhD

The assistant professor of neurology at Johns Hopkins Medicine talked about her preclinical research in immunology to explore the intricate mechanisms controlling chronic inflammation in the central nervous system. [WATCH TIME: 5 minutes]

Givinostat's Multifactorial Mechanism of Action in Duchenne Muscular Dystrophy: Marcello Paglione, PhD

The executive medical lead at Italfarmaco SpA expressed his confidence in givinostat to mitigate the progression of Duchenne muscular dystrophy, emphasizing its multifactorial mechanism of action. [WATCH TIME: 5 minutes]

Targeting Neurodegeneration to Impart Neuroprotection in Progressive MS: Shiv Saidha, MBBCh

The professor of neurology at Johns Hopkins Medicine discussed the limited impact of current therapies on retinal atrophy rates in progressive multiple sclerosis at the 2024 ACTRIMS Forum. [WATCH TIME: 5 minutes]

Evaluating Givinostat's Efficacy and Safety in Duchenne Muscular Dystrophy: Marcello Paglione, PhD

The executive medical lead at Italfarmaco SpA talked about data from both animal models and clinical trials supporting the efficacity of givinostat in patients with Duchenne muscular dystrophy at MDA 2024. [WATCH TIME: 5 minutes]

Elixirgen Therapeutics’ Bobcat mRNA Therapeutic for Duchenne Muscular Dystrophy: Aki Ko

The chief executive officer at Elixirgen Therapeutics discussed the company’s mRNA as a promising therapeutic avenue for Duchenne muscular dystrophy. [WATCH TIME: 6 minutes]

AC Immune SA Shares Phase 2 VacSYn Trial Update for ACI-7104.056 in Parkinson Disease

Analyzing Cognitive Profiles in Multiple Sclerosis and Alzheimer Disease: Le Hua, MD

The director of the Multiple Sclerosis Program at the Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed findings from a study that compared cognitive profiles between patients with multiple sclerosis and Alzheimer disease. [WATCH TIME: 5 minutes]

Integrating Genetics and Transitional Support in Muscular Dystrophy Care: Amanda Peltier, MD

The professor of neurology at Vanderbilt University Medical Center discussed advocating for reinstating personalized resources, expanding genetic testing, and improving transitional care in muscular dystrophy. [WATCH TIME: 5 minutes]

Promising Preclinical Evidence of Skeletal Muscle Regenerator SAT-3247: Frank Gleeson

The president and chief executive officer of Satellos Bioscience provided an overview of the previously observed preclinical data supporting SAT-3247 as a potential therapy for muscular dystrophies. [WATCH TIME: 4 minutes]

A Patient Perspective on Gene Therapy for Neuromuscular Diseases: Justin Moy

The second-year PhD student in bioinformatics at Boston University who lives with LAMA2 congenital muscular dystrophy talked about the potential impact and challenges of gene therapy in neuromuscular diseases. [WATCH TIME: 5 minutes]

Enhancing Multidisciplinary Care for Neuromuscular Disorders: Amanda Peltier, MD

The professor of neurology at Vanderbilt University Medical Center talked about the importance of multidisciplinary care centers to improve accessibility and quality of care for patients with neuromuscular disorders. [WATCH TIME: 5 minutes]

Targeting the NLRX1 Pathway for Neuroprotection in Multiple Sclerosis: Marjan Gharagozloo, PhD

The assistant professor of neurology at Johns Hopkins Medicine talked about recent research that suggests activating the NLRX1 pathway could offer neuroprotection in multiple sclerosis. [WATCH TIME: 5 minutes]

Therapeutic Avenues for Multiple Sclerosis Through Immune Cell Communication: Jeffrey Huang, PhD

The associate professor of biology at Georgetown University talked about how immune cells can communicate with brain cells to enhance repair processes, which may offer potential treatment targets for multiple sclerosis. [WATCH TIME: 5 minutes]

Clinical Benefits to Emphasizing Patient Voices in ALS: Brooke Eby

A patient advocate within the ALS community discussed the importance of incorporating patients and their voices into clinical meetings and trial design to ultimately meet treatment goals. [WATCH TIME: 4 minutes]

Overviewing Phase 2 SYNAPSE-SMA Trial of NMD670 for Spinal Muscular Atrophy: Jorge Quiroz, MD, MBA

The chief medical officer of NMD Pharma provided perspective on a newly launched phase 2 study assessing NMD670, a first-in-class neuromuscular transmission enhancer, in patients with spinal muscular atrophy type 3. [WATCH TIME: 5 minutes]

Episode 111: Reviewing ACTRIMS 2024

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 32 minutes]

Data Showcases Promising Mechanism of Action of GT-02287 for Parkinson Disease

Clinical Significance of Visual System Modeling for Multiple Sclerosis Research: Shiv Saidha, MBBCh

The professor of neurology at Johns Hopkins Medicine talked about modeling visual systems as an area of focus in clinical trials for multiple sclerosis as it may offer insights into neurodegeneration and neuroprotection. [WATCH TIME: 6 minutes]

Combination Therapy of CST-2032/CST-107 Shows Promise in Treating Cognitive Impairment in Phase 2a Trial

Desert Mapping to Promote Health Equity in Multiple Sclerosis Care: Julie Fiol, MSCN; Andreina Barnola, MD, MPH

The associate vice president of clinical Innovation and strategy and the health equity director at National MS Society talked about leveraging data mapping to bridge healthcare gaps and promote health equity in multiple sclerosis. [WATCH TIME: 4 minutes]

Flaws in Assessment Scales for Neuromuscular Conditions: Laurent Servais, MD, PhD

The professor of pediatric neuromuscular diseases at the University of Oxford provided commentary on the commonly used scales to assess neuromuscular function and where inconsistencies have been observed. [WATCH TIME: 7 minutes]

NeuroVoices: Aki Ko, on mRNA Therapeutics for Duchenne Muscular Dystrophy

The chief executive officer at Elixirgen Therapeutics provided commentary on the promise of the Bobcat mRNA, and the mechanism of action for mRNA-like therapies to treat Duchenne muscular dystrophy.

Association Between Obesity and Disease Progression in Multiple Sclerosis: Lars Alfredsson, PhD

The professor of epidemiology at Karolinska Institutet talked about findings from a comprehensive study on the correlation between obesity and accelerated progression of multiple sclerosis. [WATCH TIME: 8 minutes]

Advancing Neural Repair Through Cellular Responses and Biomarkers in MS Models: Jenn Orthmann-Murphy, MD, PhD

The assistant professor of neurology in the Perelman School of Medicine at University of Pennsylvania discussed preclinical research on neural repair in multiple sclerosis at ACTRIMS Forum 2024. [WATCH TIME: 4 minutes]

Improving MS Care Through Innovative Trial Designs: Daniel Ontaneda, MD, PhD

Following the 2024 ACTRIMS Forum, the associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided insight on the need to build creative trials for multiple sclerosis treatments. [WATCH TIME: 3 minutes]

Exploring the Potential Therapeutic Avenue of BTK Inhibitors for Progressive MS: Amit Bar-Or, MD, FRCPC, FAAN, FANA

The Melissa and Paul Anderson President’s Distinguished Professor of Neurology, Perelman School of Medicine, University of Pennsylvania, discussed the promising avenue of BTK inhibitors for addressing progressive multiple sclerosis. [WATCH TIME: 5 minutes]